M J Pérez-Sáez 1 2 3, S Herrera 2 4 5, D Prieto-Alhambra 2 5 6, L Vilaplana 2 4 5, X Nogués 2 4 5, M Vera 1 2, D Redondo-Pachón 1 2 3, M Mir 1 2, R Güerri 2 4 5, M Crespo 1 2 3, A Díez-Pérez 7 8 9, J Pascual 10 11 12 Osteoporos Int. 2017 Sep;28(9):2723-2727. doi: 10.1007/s00198-017-4065-5. Epub 2017 May […]
S Herrera 1, R Soriano 1, X Nogués 1, R Güerri-Fernandez 1, D Grinberg 2, N García-Giralt 1, N Martínez-Gil 2, S Castejón 1, A González-Lizarán 1, S Balcells 2, A Diez-Perez 3 4 Osteoporos Int. 2017 Dec;28(12):3489-3493. doi: 10.1007/s00198-017-4198-6. Epub 2017 Aug 25. PMID: 28842728
Sabina Herrera 1, Jordi Pérez-López 2, Marc Moltó-Abad 2, Roberto Güerri-Fernández 1, Elena Cabezudo 3, Silvana Novelli 4, Jordi Esteve 5, Albert Hernández 6, Inmaculada Roig 7, Xavier Solanich 8, Daniel Prieto-Alhambra 9 10, Xavier Nogués 1, Adolfo Díez-Pérez 1 J Bone Miner Res. 2017 Jul;32(7):1575-1581. doi: 10.1002/jbmr.3121. Epub
J R Starr 1, G Tabacco 1 2, R Majeed 1, B Omeragic 1, L Bandeira 1 3, M R Rubin 4 Osteoporos Int. 2020 Feb;31(2):327-333. doi: 10.1007/s00198-019-05177-2. Epub 2019 Nov 13. PMID: 31720712 DOI: 10.1007/s00198-019-05177-2 PTH levels
Manuela Schoeb 1, Elizabeth M Winter 1, Maria A Sleddering 1, Mirjam A Lips 1, Abbey Schepers 2, Marieke Snel 1, Natasha M Appelman-Dijkstra 1 J Clin Endocrinol Metab. 2021 Jun 16;106(7):e2527-e2534. doi: 10.1210/clinem/dgab207. PMID: 33780545
Anna G Nilsson 1, Daniel Sundh 1, Lisa Johansson 1, Martin Nilsson 1, Dan Mellström 1, Robert Rudäng 1, Michail Zoulakis 1, Märit Wallander 1 2, Anna Darelid 1, Mattias Lorentzon 1 J Bone Miner Res. 2017 May;32(5):1062-1071. doi: 10.1002/jbmr.3057. Epub 2017 Jan
Jessica R Furst 1, Leonardo C Bandeira 1, Wen-Wei Fan 1, Sanchita Agarwal 1, Kyle K Nishiyama 1, Donald J McMahon 1, Elzbieta Dworakowski 1, Hongfeng Jiang 1, Shonni J Silverberg 1, Mishaela R Rubin 1 J Clin Endocrinol
J Bone Miner Res. 2014 Apr;29(4):787-95. doi: 10.1002/jbmr.2106. PMID: 24123088 PMCID: PMC3961509 DOI: 10.1002/jbmr.2106 Although patients with type 2 diabetes (T2D) are at significant risk
Indication For Use and Safety Information
The OsteoProbe is indicated for use as a measurement tool to measure bone tissue resistance to microindentation on the tibia in adults. The clinical significance of resistance to microindentation is unknown. The device is not intended to diagnose or treat any clinical condition.
Like with any percutaneous procedure, there is a small risk of infection. The sale, distribution, and use of the OsteoProbe are restricted to prescription use. Federal law (United States of America) restricts this device to use by, or on the order of, a physician.
This website uses cookies to enhance the user experience. By using this site you agree to our privacy policy
This website uses cookies to enhance the user experience. By using this site you agree to our privacy policy